HEALTHSOUTH®



First Quarter 2012 Earnings Call

Supplemental Slides

Forward-Looking Statements

The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect our current outlook, views and plans with respect to future events, including legislative and regulatory developments, strategy, capital expenditures, development activities, dividend strategies, effective tax rates, financial performance, and business model. These estimates, projections and other forward-looking information are based on assumptions that HealthSouth believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material.

There can be no assurance that any estimates, projections or forward-looking information will be realized.

All such estimates, projections and forward-looking information speak only as of the date hereof. HealthSouth undertakes no duty to publicly update or revise the information contained herein.

You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended March 31, 2012, when filed, and in other documents we previously filed with the SEC, many of which are beyond our control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein.

Note Regarding Presentation of Non-GAAP Financial Measures

The following presentation includes certain "non-GAAP financial measures" as defined in Regulation G under the Securities Exchange Act of 1934. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. Our Form 8-K, dated April 26, 2012, to which the following supplemental slides are attached as Exhibit 99.2, provides further explanation and disclosure regarding our use of non-GAAP financial measures and should be read in conjunction with these supplemental slides.

Table of Contents

Q1 2012 Summary (Q1 2012 vs. Q1 2011)..... 4-6
Revenues (Q1 2012 vs. Q1 2011)..... 7
Expenses (Q1 2012 vs. Q1 2011)..... 8
Adjusted EBITDA..... 9
Earnings per Share..... 10
Adjusted Free Cash Flow 11-12
2012 Guidance - Adjusted EBITDA 13
2012 Guidance - EPS 14
Income Tax Considerations..... 15
Adjusted Free Cash Flow Considerations..... 16
Priorities for Reinvesting Free Cash Flows..... 17
Portfolio Growth..... 18
Appendix..... 19
Business Outlook: 2012 to 2014..... 20-22
Historic Discharge Growth vs. Industry..... 23
Our Track Record..... 24-25
Debt and Liquidity..... 26
Debt Maturity Profile..... 27
Debt Schedule..... 28
Revenues & Expenses (Sequential)..... 29
Payment Sources (Percent of Revenues) 30
Operational and Labor Metrics..... 31
Outstanding Share Summary and Warrant Information..... 32
Adjusted EBITDA History..... 33
Adjusted Free Cash Flow 34
Reconciliations to GAAP..... 35-39


HEALTHSOUTH


Q1 2012 Summary (Q1 2012 vs. Q1 2011)

- ✓ **Q1 2012 benefited from an additional day in February due to leap year.**

- ✓ **Revenue growth of 6.4%**
  - — Inpatient revenue growth of 8.3%
    - Discharge growth of 6.0%; same-store discharge growth of 5.0%
    - Revenue per discharge increase of 2.2%
  - — Outpatient and other revenue declined by 13.4% ($5.9 million)
    - Q1 2011 outpatient and other revenue benefited by approx. $3.4 million nonrecurring state provider tax revenue.

- ✓ **Improved operating leverage and improved labor productivity**





- ✓ **Adjusted EBITDA (3) for the quarter of $127.0 million reflects growth of 8.1%.**
  - — Q1 2011 Adjusted EBITDA benefited by approx. $1.5 million for nonrecurring net state provider tax revenue.

(1) General & Administrative excludes stock-based compensation.
(2) Hospital-related expenses include other operating expenses, supplies, and occupancy costs.
(3) Reconciliation to GAAP provided on slides 35, 36, 38, and 39.

HEALTHSOUTH


Q1 2012 Summary (Q1 2012 vs. Q1 2011) (cont.)

- ✓ **Adjusted free cash flow [1] for the quarter of $45.2 million**
  - — Q1 2012 adjusted free cash flow reflected the planned investment in the clinical information system, the anticipated increase in net working capital, and other items, as illustrated on slide 11.
- ✓ **Repurchased 25,000 shares of our convertible perpetual preferred stock for $25 million**
  - — Reduces annual preferred stock dividend payments by $1.6 million and diluted share count by 0.8 million shares
- ✓ **Diluted earnings [2] per share of $0.40 reflect strong operating results and an effective tax rate of approx. 40% [3] for the quarter (see table on slide 10)**

(1) Reconciliation to GAAP provided on slide 34
(2) Income from continuing operations attributable to HealthSouth
(3) Estimated effective tax rate using pre-tax income from continuing operations attributable to HealthSouth

Q1 2012 Summary (Q1 2012 vs. Q1 2011) (cont.)

✓ HealthSouth Functional Outcomes Continue to Outpace Industry Average



FIM Gain
Change in Functional Independence Measurement (based on an 18 point assessment) from admission to discharge.

LOS Efficiency
Functional gain divided by length of stay.

* Average = Expected, Risk-adjusted

Source: UDSmr Database – On Demand Report: **Q1 2012 Report**

HEALTHSOUTH

Revenues (Q1 2012 vs. Q1 2011)

(Millions)	Q1 2012	Q1 2011	Increase/ (Decrease)
Inpatient	$ 500.6	$ 462.1	8.3%
Outpatient and other	38.0	43.9	(13.4%)
Consolidated net operating	$ 538.6	$ 506.0	6.4%

(Actual Amounts)			
Discharges	30,871	29,127	6.0%
Net patient revenue / discharge	$16,216	$15,865	2.2%

- ✓ **Revenue growth of 6.4%**
  - — Inpatient revenue growth of 8.3%
    - ▪ Discharge growth of 6.0%; same-store discharge growth of 5.0%
    - ▪ Revenue per discharge increase of 2.2%
      - • Price adjustments (Medicare and managed care)
      - • Higher percentage of neurological cases increased the average acuity (CMI) for the patients we served
      - • Higher percentage of Medicare patients
  - — Outpatient and other revenue declined by 13.4% ($5.9 million)
    - ▪ Q1 2011 outpatient and other revenue benefited by approx. $3.4 million nonrecurring state provider tax revenue.
    - ▪ Six fewer outpatient rehabilitation satellite clinics in Q1 2012

Expenses (Q1 2012 vs. Q1 2011)

(Millions)	Q1 2012	Q1 2011	Increase/ (Decrease)
Salaries and benefits	$ 261.0	$ 244.0	7.0%
Percent of net operating revenues	48.5%	48.2%	30 bps
EPOB (employees per occupied bed)	3.34	3.39	(1.5%)
Hospital-related expenses (other operating, supplies, occupancy)	$ 112.0	$ 108.3	3.4%
Percent of net operating revenues	20.8%	21.4%	(60 bps)
General and administrative (excludes stock-based compensation)	$ 23.9	$ 22.7	5.3%
Percent of net operating revenues	4.4%	4.5%	(10 bps)
Provision for doubtful accounts	$ 6.3	$ 4.8	31.3%
Percent of net operating revenues	1.2%	0.9%	30 bps

- ✓ **Improved operating leverage and labor productivity (EPOB) was offset by:**
  - Increased installation and operating expenses for new clinical information system of $1.6 million
  - Ramp-up costs at two new hospitals (Cypress and Drake)
  - SWB as a percent of revenue impacted by:
    - Higher SWB per employee as a result of merit increases for non-executive employees and a higher skills mix
    - Q1 2011 outpatient and other revenue includes approx. $3.4 million nonrecurring state provider revenue

Adjusted EBITDA (1)

(Millions)	Q1 2012	Q1 2011
Net operating revenues	$ 538.6	$ 506.0
Less: Provision for doubtful accounts	(6.3)	(4.8)
Net operating revenues less provision for doubtful accounts	532.3	501.2
Operating expenses:		
Salaries and benefits	(261.0)	(244.0)
Hospital-related expenses:		
Other operating expenses	(73.0)	(70.9)
Supplies	(26.5)	(25.8)
Occupancy costs	(12.5)	(11.6)
	(112.0)	(108.3)
General and administrative expenses (2)	(23.9)	(22.7)
Equity in nonconsolidated affiliates	3.3	2.5
Other income	0.9	0.6
Noncontrolling interests (3)	(12.6)	(11.8)
Adjusted EBITDA	**$ 127.0**	**$ 117.5**

(1) Reconciliation to GAAP provided on slides 35, 36, 38, and 39.

In arriving at Adjusted EBITDA, the following were excluded:	Q1 2012	Q1 2011
(2) Stock-based compensation expense	6.1	4.2
(3) Noncontrolling interests related to discontinued operations	-	(0.1)

Adjusted EBITDA Change

Q1 2012
+$9.5M
+8.1%

- **Revenue growth**
- **Improved operating leverage and labor productivity**
- **Q1 2011 benefited by approx. $1.5 million of nonrecurring net state provider tax revenue**
- **Higher bad debt expense**

Earnings per Share

(In Millions, Except Per Share Data)	Q1 2012	Q1 2011
Adjusted EBITDA	$ 127.0	$ 117.5
Interest expense and amortization of debt discounts and fees	(23.3)	(35.1)
Depreciation and amortization	(19.5)	(19.5)
Stock-based compensation expense	(6.1)	(4.2)
Other, including non-cash loss on disposal of assets	(0.8)	(0.1)
	77.3	58.6
Certain nonrecurring expenses:		
Professional fees - accounting, tax, and legal	(3.6)	(3.8)
Pre-tax income	73.7	54.8
Income tax (expense) benefit [1]	(29.1)	7.4 [2]
Income from continuing operations [3]	$ 44.6	$ 62.2
Basic shares	94.5	93.1
Diluted shares	108.7	109.0
Basic earnings per share [3] [4]	$ 0.40	$ 0.60
Diluted earnings per share [3]	$ 0.40 [5]	$ 0.57

Earnings per Share from Continuing Operations [3]


Q1 2012 reflects:

- **Higher Adjusted EBITDA**
- **Decreased interest expense**
- **Approx. 40%[6] effective tax rate**

(1) Cash income tax expense for the three months ended March 31, 2012 and 2011 was $2.1million and $2.6 million, respectively.
(2) Includes a $0.27 per diluted share benefit primarily related to the Company's settlement with the IRS for tax years 2007 and 2008 and a reduction in unrecognized tax benefits due to the lapse of the statute of limitations for certain federal and state claims
(3) Income from continuing operations attributable to HealthSouth
(4) The dividends related to our convertible perpetual preferred stock must be subtracted from income from continuing operations when calculating basic earnings per share.
(5) Diluted earnings per share on a GAAP basis are the same as basic earnings per share due to the antidilutive impact in the period.
(6) Estimated effective tax rate using pre-tax income from continuing operations attributable to HealthSouth

Adjusted Free Cash Flow[1]

(Millions, except per share data)	Q1 2012	Q1 2011	Change $	Change %
Adjusted free cash flow [1]	$ 45.2	$ 48.2	$ (3.0)	(6.2%)



(1) Reconciliation to GAAP provided on slide 34
(2) Reflects lower average borrowings and lower average interest rate
(3) Reflects change in timing of interest payments as a result of capital structure changes in the last 12 months
(4) Payroll tax withholdings related to the vesting of a 2009 grant of restricted stock awards to employees
(5) Final swap payment was made in March 2011.
(6) Planned investment in clinical information system and hospital refresh projects

HEALTHSOUTH

Adjusted Free Cash Flow (cont.)

(Millions)	Q1 2012	Q1 2011	Full Year 2011
Net cash provided by operating activities	$ 81.0	$ 89.5	$ 342.7
Impact of discontinued operations	(0.4)	(2.1)	(9.1)
Net cash provided by operating activities of continuing operations	80.6	87.4	333.6
Capital expenditures for maintenance	(19.1)	(9.1)	(50.8)
Net settlements on interest rate swaps	-	(10.9)	(10.9)
Dividends paid on convertible perpetual preferred stock	(6.8)	(6.5)	(26.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(13.1)	(13.7)	(44.2)
Non-recurring items:			
Cash paid for professional fees - accounting, tax and legal	3.6	3.8	21.0
Net premium on bond issuance/repayment	-	(4.1)	22.8
Cash paid for government, class action and related settlements	-	4.3	5.7
Income tax refunds related to prior periods	-	(3.0)	(7.9)
Adjusted free cash flow	**$ 45.2**	**$ 48.2**	**$ 243.3**

✓ **Adjusted free cash flow for the quarter of $45.2 million**

- Q1 2012 adjusted free cash flow reflected the planned investment in the clinical information system, the anticipated increase in net working capital, and other items, as illustrated on slide 11.

2012 Guidance – Adjusted EBITDA [1]

2012 Adjusted EBITDA
$475 million to $485 million

Based on results of Q1 2012, HealthSouth expects its 2012 full year results to be at the high end of, or greater than, this guidance range.

Considerations:

- ✓ **Revenue growth of 3.8% to 5.2% (April through December 2012)**
  - — Discharge growth between 2.5% and 3.5% (April through December 2012)
  - — Revenue per discharge growth between 2.0% and 2.5% (April through December 2012)
  - — Home health revenues subject to approx. $1.0 million reduction related to the 2012 Medicare Home Health rule
- ✓ **Higher bad debt expense of approx. 1.3% of revenues (approx. $6 million more than 2011)**
- ✓ **Installation of new clinical information system in twelve existing hospitals expected to increase operating expenses by approx. $4 million in 2012**
- ✓ **Higher workers' compensation expense of approx. $5 million primarily as a result of favorable actuarial adjustments in 2011**
- ✓ **Q4 2011 Adjusted EBITDA benefited by $2.4 million for nonrecurring franchise tax recovery**

[1] Reconciliation to GAAP provided on slides 35, 36, 38, and 39.

2012 Guidance - EPS

Earnings per Share from Continuing Operations Attributable to HealthSouth [1]

$1.32 to $1.39

Based on results of Q1 2012, HealthSouth expects its 2012 full year results to be at the high end of, or greater than, this guidance range.

Considerations:

- ✓ Assumes provision for income tax of approx. 40% in 2012 vs. approx. 19% in 2011 [2]
- ✓ Cash taxes expected to be $7 to $10 million
- ✓ Basic share count of 94.5 million shares

	EPS Guidance		
	Actual	Low	High
(In Millions, Except Per Share Data)	2011	2012	
Adjusted EBITDA	**$ 466.2**	**$ 475**	**$ 485**
Interest expense and amortization of debt discounts and fees	(119.4)	(96)	
Depreciation and amortization	(78.8)	(82)	
Stock-based compensation expense	(20.3)	(23)	
Other, including non-cash loss on disposal of assets	(4.3)	(7)	
	243.4	267	277
Certain Nonrecurring Expenses:			
Government, class action and related settlements	12.3	-	
Professional fees - accounting, tax and legal	(21.0)	(15)	
Loss on early extinguishment of debt	(38.8)	-	
Pre-tax income	**195.9**	**252**	**262**
Income tax (assumes 40% in 2012)	(37.1) [3]	(101)	(105)
Income from continuing operations [1]	**$ 158.8**	**$ 151**	**$ 157**
Basic shares	93.3	94.5	94.5
Earnings per share [1][4]	**$ 1.42**	**$ 1.32**	**$ 1.39**

(1) Income from continuing operations attributable to HealthSouth
(2) Estimated effective tax rate using pre-tax income from continuing operations attributable to HealthSouth
(3) Includes an approx. $46 million, or $0.49 per share, benefit primarily related to the Company's settlement with the IRS for tax years 2007 and 2008, a decrease in the valuation allowance, and a reduction in unrecognized tax benefits due to the lapse of the statute of limitations for certain federal and state claims
(4) The dividends related to our convertible perpetual preferred stock must be subtracted from income from continuing operations when calculating basic earnings per share.

HEALTHSOUTH

Income Tax Considerations

GAAP Considerations:

- As of 3/31/12, the Company had an ending balance of approx. $1.2 billion in federal NOLs and a remaining valuation allowance of approx. $50 million, primarily related to state NOLs.
- 2011 effective tax rate was approx. 19%. (1)(2)
- Expect effective tax rate of approx. 40% (1) going forward

Future Cash Tax Payments:

- The Company expects to pay approx. $7 million to $10 million per year of income tax.
- HealthSouth is not currently subject to an annual use limitation ("AUL") under Internal Revenue Code Section 382 ("Section 382"). A "change of ownership," as defined by Section 382, would subject the Company to an AUL, which is equal to the market capitalization of the Company at the time of the "change of ownership" multiplied by the long-term tax exempt rate.

(1) Estimated effective tax rate using pre-tax income from continuing operations attributable to HealthSouth

(2) Includes an approx. $46 million, or $0.49 per share, benefit primarily related to the Company's settlement with the IRS for tax years 2007 and 2008, a decrease in the valuation allowance, and a reduction in unrecognized tax benefits due to the lapse of the statute of limitations for certain federal and state claims

Adjusted Free Cash Flow [1] Considerations

- **2012 adjusted free cash flow growth reflects increased maintenance capital expenditures and working capital.**
- **Multi-year adjusted free cash flow CAGR of 12% to 17%**

Certain Cash Flow Items [2] (millions)	2011 Actual	Q1 2012 Actual	2012 Assumptions
Cash interest expense [3]	$115.2	$22.4	$92
Cash payments for taxes	$9.1	$2.5	$7 to $10
Working capital	$10.6	$31.0	$30-$40
Maintenance CAPEX	$50.8	$19.1	$75 to $85
Net cash swap-related settlements	$10.9	-	-
Dividends paid on preferred stock [4]	$26	$6.8	$25.1

The increase in 2012 maintenance CAPEX is driven by the clinical information system roll-out, two major hospital renovations, and increased hospital refresh projects.

(1) Reconciliation to GAAP provided on slide 34
(2) Definition of adjusted free cash flow is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, net settlements on interest rate swaps, dividends paid on preferred stock, distributions to noncontrolling interests, and nonrecurring items.
(3) Net of amortization of debt and discounts and fees
(4) Q1 2012 includes cash dividend payments of $6.5 million for dividends declared in Q4 2011 and paid in Q1 2012 plus $0.3 million for cumulative dividends paid for the shares repurchased in Q12012. Assumptions for 2012 include the $6.8 Q1 2012 dividends paid plus expected cash dividends of $6.1 million for each of the remaining three quarters.

Priorities for Reinvesting Free Cash Flows

Priorities

Growth

- **Growth in core business**
  - Bed expansions (80-100 beds)
  - De novo hospitals (complete Ocala; start 4 others)
  - Acquisitions (target 2/year)
    - Free standing IRFs
    - Hospital unit

(millions)

	2012 Assumptions	Q1 2012 Actual
Bed expansions (80-100 beds)	$20 to $25	$5.5
De novo hospitals (complete Ocala; start 4 others)	$50 to $70	$9.2
Acquisitions (target 2/year)	TBD	-
	$70 to $95, excluding acquisitions	$14.7

Alternate Opportunities

Debt Reduction

	Q1 2012 Actual
Debt prepayment	-
Purchase leased properties (limited opportunity)	-

Shareholder Distribution

	Q1 2012 Actual
Convertible preferred stock repurchase ($125 million authorization)	$25.0
Common share repurchase ($125 million authorization)	-
Cash dividends (one time or regular)	-
	$25.0

Portfolio Growth

- All projects have minimum IRR of 15% (pre-tax).

De novos

- **Cash Payback [1] = 5 to 7 years**
- **Longer payback period due to:**
  - Design and construction period
  - Initial ramp-up of operations
- **Target 4 openings/Year**

Acquisitions

- **Cash Payback [1] = 4 to 6 years**
- **Target: 2 acquisitions/Year**

	De novos			Acquisitions		
	Location	**Installed Beds**	**Operational Date**	**Location**	**Beds**	**Operational Date**
2013 [2]	Stuart, FL	34	Q2 2013	TBD	TBD	TBD
	Littleton, CO	40	Q2 2013			
	Southwest Phoenix, AZ	40	Q3 2013			
2012	Ocala, FL	40	Q4 2012	TBD	TBD	TBD
2011	Cypress, TX	40	Q4 2011	Cincinnati, OH	40	Q4 2011
2010	Bristol, VA	25	Q3 2010	Ft. Smith, AR (unit)	30	Q3 2010
				Sugarland, TX (IRF)	50	Q3 2010
	Loudoun County, VA	40	Q2 2010	Las Vegas, NV (IRF)	50	Q2 2010
				Little Rock, AR (unit)	23	Q1 2010
2009	Mesa, AZ	40	Q3 2009	Altoona, PA (JV, unit)	18	Q4 2009

(1) Future cash payback periods may increase when the Company exhausts its significant NOLs (slide 15).
(2) Does not include Middletown, DE or Williams Co., TN where CON awards are under appeal

Appendix

Business Outlook: 2012 to 2014

Business Model

- **Adjusted EBITDA CAGR: 5-8%** (1)(2)
- **Adjusted Free Cash Flow CAGR: 12-17%** (1)(2)

Strategy	2011	2012	2013	2014
Delevering (3)	Achieved **< 3.0x** Debt to EBITDA	**< 3.0x** Debt to EBITDA (subject to operating environment)		
Core Growth	**Same-store Growth** (Includes bed expansions and unit consolidations)			
	De novos 1- Cypress, TX	**De novos** 1- Ocala, FL	**De novos** (target of 4/year)	
	IRF Acquisitions 1- Drake, OH	**IRF Acquisitions** (target of 2/year)		
Opportunistic Growth			**Consider opportunistic, disciplined acquisitions** of complementary post-acute services	
Key Operational Initiatives	• **Clinical Information System (CIS)** Pilot	• **CIS** Company-wide Implementation		
	• **Beacon** (Management Reporting Software) = Labor / outcomes / quality optimization • **TeamWorks** = Care Management • **"CPR"** (Comfort, Professionalism, Respect) Initiative			

Key Considerations:
- Regulatory clarity
- Market conditions
- Purchase price and terms and conditions

(1) Reconciliation to GAAP provided on slides 35, 36, 38, and 39.
(2) These are multi-year CAGRs; annual results may fall outside the range.
(3) Exclusive of any E&Y recovery.


Business Outlook: Revenue Assumptions

Revenue

Volume

- 2.5% to 3.5% annual growth (excludes acquisitions)
- Includes bed expansions, de novos and unit consolidations

Pricing



Medicare Pricing	FY 2012 (1) Q4 11 - Q3 12	FY 2013 Q4 12 - Q3 13	FY 2014 Q4 13 - Q3 14
Market basket update (2)	2.9%	2.9%	2.9%
Healthcare reform reduction	10 bps	10 bps	30 bps
Productivity adjustment (2)	100 bps	90 bps	~ 110 bps

Managed Care Expected Price Increases		
2012	2013	2014
3-5%	3-5%	3-5%

2% Sequestration (3)

(1) We believe based on the Medicare IRF-PPS Rule for FY 2012, HealthSouth should realize a net increase of approximately 1.6% in 2012.
(2) Medicare IRF-PPS Rule for FY 2012, CMS Current Economic Index for FY 2013, and management estimates for FY 2014.
(3) The Budget Control Act of 2011 includes a reduction of up to 2% to Medicare payments for all providers upon executive order of the President in January 2013. The reduction would be made from whatever level of payment would otherwise be provided under Medicare law and regulation. We currently estimate this automatic reduction, known as "sequestration," will result in a net decrease to our net operating revenues of approx. $32 million in 2013.

HEALTHSOUTH

Business Outlook: Expense Assumptions


Expense

Salaries & Benefits (1)

	2012	2013	2014
Merit increases (2)	2.25-2.5%	2.25-2.5%	2.25-2.5%
Benefit costs increases	5-8%	5-8%	5-8%

Hospital Expenses

- Other operating expenses and supply costs tracking with inflation
- Occupancy costs relatively constant as percent of revenue
- Bad debt expense of approx. 1.3% to1.5%



General and Administrative

~4.5% of revenue

(excludes stock-based compensation)


(1) Salaries, Wages and Benefits: ~ 90% Salaries and Wages; ~10% Benefits.

(2) May be adjusted to offset the Budget Control Act of 2011 or other Medicare reduction legislation


Historic Discharge Growth vs. Industry

HealthSouth's volume growth has outpaced competitors'

Same Store HealthSouth vs. Industry



Quarterly Discharge Growth



Yearly Discharge Growth	6.9%	5.6%	3.1%	5.2%

- TeamWorks = standardized and enhanced sales & marketing
- Bed additions will help facilitate continued organic growth


(1) Data provided by UDSMR, a data gathering and analysis organization for the rehabilitation industry; represents ~ 65-70% of industry, including HealthSouth sites.
(2) Includes consolidated HealthSouth inpatient rehabilitation hospitals classified as same store during that time period.

HEALTHSOUTH


Our Track Record

($ in millions)


Revenue




Discharge Volume



Adjusted EBITDA (1)



Income from Continuing Operations Attributable to HealthSouth (2)




(1) Reconciliation to GAAP provided on slides 35 - 39.

(2) 2010 includes an income tax benefit of ~$741 million primarily due to the reversal of a substantial portion of the valuation allowance against deferred tax assets.


HEALTHSOUTH

Our Track Record

Total Debt



Adjusted Free Cash Flow (1)




(1) Based on 2007 and trailing 4 Qtrs Adjusted EBITDA of $306.7 million and $475.7 million, respectively; reconciliation to GAAP provided on slides 34 - 39.

HEALTHSOUTH

Debt and Liquidity

Debt Outstanding



Liquidity

	March 31, 2012	Dec. 31, 2011
Cash Available	$ 44.3	$ 30.1
Revolver Total Line	$ 500.0	$ 500.0
Less:		
– Draws	(125.0)	(110.0)
– Letters of credit	(44.4)	(44.6)
Available	$ 330.6	$ 345.4
Total Liquidity	$ 374.9	$ 375.5

Credit Ratings

	S&P	Moodys
Corporate Rating	B+ Positive	B1 Positive
Revolver Rating	BB	Ba1
Senior Notes Rating	B+	B2

(1) Based on 2008 and trailing 4 quarters Adjusted EBITDA of $322.6 million and $475.7 million, respectively; reconciliation to GAAP provided on slides 35 – 39.

HEALTHSOUTH


Debt Maturity Profile

HealthSouth is now positioned with a lower-cost, flexible capital structure…

- Additional debt pre-payment opportunities and flexible covenants (1)
- No near-term maturities and well-spaced debt maturities
- Limited exposure to higher interest rates

March 31, 2012 (2)

($ in millions)



(1) The credit agreement has a $200 million restricted payment basket for debt repayment and stock repurchases, which is subject to an annual grower basket equal to 50% of excess cash flow plus certain other amounts including net cash proceeds from certain equity issuances.

(2) Does not include $363.2 million of convertible perpetual preferred stock and capital leases and other note payables.

HEALTHSOUTH

Debt Schedule

(Millions) Corporate	Credit Rating S&P	Credit Rating Moody	March 31, 2012	Dec. 31, 2011	Change in Debt vs. YE 2011
	B+	B1			
Advances under $500 million revolving credit facility, May 2016 - 3 Month LIBOR +225bps	BB	Ba1	$ 125.0	$ 110.0	$ 15.0
Term loan facility, May 2016 - 3 Month LIBOR +225bps	BB	Ba1	96.3	97.5	(1.2)
Bonds Payable:					
7.25% Senior Notes due 2018	B+	B2	336.7	336.7	-
8.125% Senior Notes due 2020	B+	B2	285.9	285.8	0.1
7.75% Senior Notes due 2022	B+	B2	311.9	312.0	(0.1)
Other bonds payable			1.5	1.5	-
Other notes payable			35.0	35.3	(0.3)
Capital lease obligations			73.0	75.9	(2.9)
Long-term debt			**$ 1,265.3**	**$ 1,254.7**	**$ 10.6**
Debt to Adjusted EBITDA [1]			**2.7x**	**2.7x**	

(1) Based on 4 Qtr trailing and 2011 Adjusted EBITDA of $475.7 million and $466.2 million, respectively; reconciliation to GAAP provided on slides 35, 36, 38, and 39.

Revenues & Expenses (Sequential)

Revenues (millions)	Q1 2012	Q4 2011	Increase/ (Decrease)
Inpatient	$ 500.6	$ 480.1	4.3%
Outpatient and other	38.0	38.0	0.0%
Consolidated net operating	$ 538.6	$ 518.1	4.0%
(Actual Amounts)			
Discharges	30,871	30,066	2.7%
Net patient revenue / discharge	$ 16,216	$ 15,968	1.6%
Expenses (millions)			
Salaries and benefits	$ 261.0	$ 251.4	3.8%
Percent of net operating revenues	48.5%	48.5%	0 bps
EPOB (employees per occupied bed)	3.34	3.46	(3.5%)
Hospital-related expenses	$ 112.0	$ 105.7	6.0%
(other operating, supplies, occupancy, bad debts)			
Percent of net operating revenues	20.8%	20.4%	40 bps
General and administrative	$ 23.9	$ 23.9	0.0%
(excludes stock-based compensation)			
Percent of net operating revenues	4.4%	4.6%	(20 bps)
Provision for doubtful acounts	$ 6.3	$ 6.1	3.3%
Percent of net operating revenues	1.2%	1.2%	0 bps

Payment Sources (Percent of Revenues)

	Q1		Full Year
	2012	2011	2011
Medicare	73.5%	71.5%	72.0%
Medicaid	1.1%	1.7%	1.6%
Workers' compensation	1.5%	1.7%	1.6%
Managed care and other discount plans [1]	19.3%	19.7%	19.8%
Other third-party payors	1.7%	2.1%	2.0%
Patients	1.4%	1.1%	1.2%
Other income	1.5%	2.2%	1.8%
Total	100.0%	100.0%	100.0%

(1) Managed Medicare revenues represent ~ 8%, 7%, and 7% of total revenues for Q1 2012, Q1 2011, and full year 2011, respectively, and are included in "Managed care and other discount plans."

Operational and Labor Metrics [1]

	Q4 2012	Q3 2012	Q2 2012	Q1 2012	Q4 2011	Q3 2011	Q2 2011	Q1 2011	3 Months 2012	3 Months 2011	Full Year 2011
						(In Millions)					
Net patient revenue-inpatient				$ 500.6	$ 480.1	$ 458.8	$ 465.4	$ 462.1	$ 500.6	$ 462.1	$ 1,866.4
Net patient revenue-outpatient and other revenues				38.0	38.0	38.9	39.7	43.9	38.0	43.9	160.5
Net operating revenues				$ 538.6	$ 518.1	$ 497.7	$ 505.1	$ 506.0	$ 538.6	$ 506.0	$ 2,026.9
						(Actual Amounts)					
Discharges [2]				30,871	30,066	29,350	29,811	29,127	30,871	29,127	118,354
Outpatient visits				231,243	225,062	236,969	244,647	236,761	231,243	236,761	943,439
Average length of stay				13.5	13.4	13.4	13.4	13.8	13.5	13.8	13.5
Occupancy %				70.7%	67.7%	67.2%	69.0%	70.2%	70.7%	70.2%	67.7%
# of licensed beds				6,500	6,461	6,376	6,356	6,350	6,500	6,350	6,461
Occupied beds				4,596	4,374	4,285	4,386	4,458	4,596	4,458	4,374
Full-time equivalents (FTEs) [3]				15,271	15,079	15,081	15,150	15,045	15,271	15,045	15,089
Contract labor				69	56	60	76	89	69	89	70
Total FTE and contract labor				15,340	15,135	15,141	15,226	15,134	15,340	15,134	15,159
EPOB [4]				3.34	3.46	3.53	3.47	3.39	3.34	3.39	3.47

(1) All metrics have been reclassified to reflect current continuing operations.

(2) Represents discharges from HealthSouth's 96 consolidated hospitals in Q1 2012 and Q4 2011; 94 consolidated hospitals in Q3 2011, Q2 2011, and Q1 2011.

(3) Excludes approximately 400 full-time equivalents who are considered part of corporate overhead with their salaries and benefits included in general and administrative expenses in the Company's consolidated statements of operations. Full-time equivalents included in the above table represent HealthSouth employees who participate in or support the operations of the Company's hospitals.

(4) Employees per occupied bed, or "EPOB," is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company's occupancy percentage.

Outstanding Share Summary and Warrant Information

(Millions)

	Weighted Average for the Period			
	Q1 2012	Q1 2011	FY 2011	FY 2010
Basic shares outstanding [1] [2]	94.5	93.1	93.3	92.8
Diluted shares outstanding [1] [2] [3]	108.7	109.0	109.2	108.5

	End of Period			
	Q1 2012	Q1 2011	FY 2011	FY 2010
Basic shares outstanding [1] [2]	94.6	93.2	93.3	92.8
Convertible perpetual preferred stock	0.375	0.400	0.400	0.400
If converted, equivalent common shares	12.3	13.1	13.1	13.1

Notes:

(1) Does not include 2.0 million warrants issued in connection with a January 2004 loan repaid to Credit Suisse First Boston. In connection with this transaction, we issued warrants to the lender to purchase two million shares of our common stock. Each warrant has a term of ten years from the date of issuance (expire January 16, 2014) and an exercise price of $32.50 per share. The warrants were not assumed exercised for dilutive shares outstanding because they were antidilutive in the periods presented.

(2) The agreement to settle our class action securities litigation received final court approval in January 2007. These shares of common stock and warrants were issued on September 30, 2009. The 5.0 million of common shares are now included in the outstanding shares. The warrants to purchase approx. 8.2 million shares of common stock at a strike price of $41.40 (expire January 17, 2017) were not assumed exercised for the dilutive shares outstanding because they were antidilutive in the periods presented.

(3) The difference between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock (Convertible into12.3 million common shares at the end of Q1 2012). The preferred stock is convertible, at the option of the holder, at any time into shares of common stock at an initial conversion price of $30.50 per share, which is equal to an initial conversion rate of approximately 32.7869 shares of common stock per share of preferred stock, subject to a specified adjustment. We may at any time cause the shares of preferred stock to be automatically converted into shares of our common stock at the conversion rate then in effect if the closing price of our common stock for 20 trading days within a period of 30 consecutive trading days ending on the trading day before the date we give the notice of forced conversion exceeds 150% of the conversion price of the preferred stock. In Q1 2012, the Company repurchased 25,000 shares of its convertible perpetual preferred stock.

Adjusted EBITDA [1] History

(Millions)	Q4 2012	Q3 2012	Q2 2012	Q1 2012	Q4 2011	Q3 2011	Q2 2011	Q1 2011	3 Months 2012	3 Months 2011	Full Year 2011
Net operating revenues				$ 538.6	$ 518.1	$ 497.7	$ 505.1	$ 506.0	$ 538.6	$ 506.0	$ 2,026.9
Less: Provision for doubtful accounts				(6.3)	(6.1)	(5.1)	(5.0)	(4.8)	(6.3)	(4.8)	(21.0)
Net operating revenues less provision for doubtful accounts				532.3	512.0	492.6	500.1	501.2	532.3	501.2	2,005.9
Operating expenses:											
Salaries and benefits				(261.0)	(251.4)	(245.0)	(241.6)	(244.0)	(261.0)	(244.0)	(982.0)
Hospital-related expenses:											
Other operating expenses				(73.0)	(67.4)	(70.3)	(75.4)	(70.9)	(73.0)	(70.9)	(284.0)
Supplies				(26.5)	(26.1)	(24.7)	(26.2)	(25.8)	(26.5)	(25.8)	(102.8)
Occupancy costs				(12.5)	(12.2)	(12.5)	(12.1)	(11.6)	(12.5)	(11.6)	(48.4)
				(112.0)	(105.7)	(107.5)	(113.7)	(108.3)	(112.0)	(108.3)	(435.2)
General and administrative expenses [2]				(23.9)	(23.9)	(21.5)	(22.1)	(22.7)	(23.9)	(22.7)	(90.2)
Equity in nonconsolidated affiliates				3.3	3.2	3.1	3.2	2.5	3.3	2.5	12.0
Other income				0.9	1.2	0.2	0.7	0.6	0.9	0.6	2.7
Noncontrolling interests [3]				(12.6)	(12.5)	(11.4)	(11.3)	(11.8)	(12.6)	(11.8)	(47.0)
Adjusted EBITDA				**$ 127.0**	**$ 122.9**	**$ 110.5**	**$ 115.3**	**$ 117.5**	**$ 127.0**	**$ 117.5**	**$ 466.2**

(1) Reconciliation to GAAP provided on slides 35, 36, 38, and 39.

	Q4 2012	Q3 2012	Q2 2012	Q1 2012	Q4 2011	Q3 2011	Q2 2011	Q1 2011	3 Months 2012	3 Month 2011	Full Year 2011
In arriving at Adjusted EBITDA, the following were excluded:											
(2) Stock-based compensation expense				$ 6.1	$ 5.9	$ 4.9	$ 5.3	$ 4.2	$ 6.1	$ 4.2	$ 20.3
(3) Noncontrolling interests related to discontinued operations				-	-	(0.1)	(0.9)	(0.1)	-	(0.1)	(1.1)

HEALTHSOUTH

Adjusted Free Cash Flow

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

	Q1		Full Year				
(Millions)	**2012**	**2011**	**2011**	**2010**	**2009**	**2008**	**2007**
Net cash provided by operating activities	$ 81.0	$ 89.5	$ 342.7	$ 331.0	$ 406.1	$ 227.2	$ 230.6
Impact of discontinued operations	(0.4)	(2.1)	(9.1)	(13.2)	(5.7)	(32.5)	(3.3)
Net cash provided by operating activities of continuing operations	80.6	87.4	333.6	317.8	400.4	194.7	227.3
Capital expenditures for maintenance [1]	(19.1)	(9.1)	(50.8)	(37.9)	(33.2)	(41.5)	(22.4)
Net settlements on interest rate swaps [2]	-	(10.9)	(10.9)	(44.7)	(42.2)	(20.7)	0.1
Dividends paid on convertible perpetual preferred stock	(6.8) [3]	(6.5)	(26.0)	(26.0)	(26.0)	(26.0)	(26.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(13.1)	(13.7)	(44.2)	(34.4)	(32.6)	(33.4)	(23.4)
Non-recurring items:							
UBS Settlement proceeds, less fees to derivative plaintiffs' attorneys	-	-	-	-	(73.8)	-	-
Net premium paid (received) on bond issuance/redemption	-	(4.1)	22.8	-	-	-	-
Cash paid for professional fees - accounting, tax and legal	3.6	3.8	21.0	17.2	15.3	18.2	51.6
Cash paid for government, class action and related settlements	-	4.3	5.7	2.9	11.2	7.4	171.4
Income tax refunds related to prior periods	-	(3.0)	(7.9)	(13.5)	(63.7)	(89.4)	(457.7)
Adjusted free cash flow	**$ 45.2**	**$ 48.2**	**$ 243.3**	**$ 181.4**	**$ 155.4**	**$ 9.3**	**$ (79.1)**

(1) Maintenance capital expenditures are expected to be $75 to $85 million in 2012.

(2) Final swap payment of $10.9 million was made in March 2011.

(3) Includes cash dividend payments of $6.5 million for dividends declared in Q4 2011 and paid in Q1 2012 plus $0.3 million for cumulative dividends paid for the shares repurchased in Q1 2012

Reconciliation of Net Income to Adjusted EBITDA [1][3]

(in millions, except per share data)	2012 Q1 Total	2012 Q1 Per Share
Net income	$ 56.8	
Loss from disc ops, net of tax, attributable to HealthSouth	0.4	
Net income attributable to noncontrolling interests	(12.6)	
Income from continuing operations attributable to HealthSouth [2]	44.6	$ 0.40
Pro fees - acct, tax, and legal	3.6	
Provision for income tax expense	29.1	
Interest expense and amortization of debt discounts and fees	23.3	
Depreciation and amortization	19.5	
Net noncash loss on disposal of assets	0.8	
Stock-based compensation expense	6.1	
Adjusted EBITDA [1][3]	$ 127.0	
Weighted average common shares outstanding:		
Basic		94.5
Diluted		108.7

(1) (2) (3) – Notes on page 38.

Reconciliation of Net Income to Adjusted EBITDA [1][3]

(in millions, except per share data)	2011 Q1 Total	2011 Q1 Per Share	2011 Q2 Total	2011 Q2 Per Share	2011 Q3 Total	2011 Q3 Per Share	2011 Q4 Total	2011 Q4 Per Share	2011 Full Year Total	2011 Full Year Per Share
Net income	$ 91.5		$ 32.3		$ 68.3		$ 62.5		$ 254.6	
(Income) loss from disc ops, net of tax, attributable to HealthSouth	(17.6)		(2.5)		(34.8)		5.0		(49.9)	
Net income attributable to noncontrolling interests	(11.7)		(10.4)		(11.3)		(12.5)		(45.9)	
Income from continuing operations attributable to HealthSouth [2]	62.2	$ 0.57	19.4	$ 0.14	22.2	$ 0.17	55.0	$ 0.50	158.8	$ 1.42
Gov't, class action, and related settlements	-		(10.6)		-		(1.7)		(12.3)	
Pro fees - acct, tax, and legal	3.8		8.4		4.0		4.8		21.0	
Provision for income tax (benefit) expense	(7.4)		11.2		18.1		15.2		37.1	
Interest expense and amortization of debt discounts and fees	35.1		34.9		26.3		23.1		119.4	
Depreciation and amortization	19.5		19.6		19.5		20.2		78.8	
Loss on early extinguishment of debt	-		26.1		12.7		-		38.8	
Net noncash loss on disposal of assets	0.1		1.0		2.8		0.4		4.3	
Stock-based compensation expense	4.2		5.3		4.9		5.9		20.3	
Adjusted EBITDA [1][3]	$ 117.5		$ 115.3		$ 110.5		$ 122.9		$ 466.2	
Weighted average common shares outstanding:										
Basic		93.1		93.3		93.3		93.3		93.3
Diluted		109.0		109.5		109.2		109.1		109.2

(1) (2) (3) – Notes on page 38.

Reconciliation of Net Income to Adjusted EBITDA [1] [3]

(in millions, except per share data)	Full Year 2007 Total	2007 Per Share	2008 Total	2008 Per Share	2009 Total	2009 Per Share	2010 Total	2010 Per Share
Net income	$ 718.7		$ 281.8		$ 128.8		$ 939.8	
Income from disc ops, net of tax, attributable to HealthSouth	(462.4)		(32.5)		(17.7)		(9.2)	
Net income attributable to noncontrolling interests	(65.3)		(29.4)		(34.0)		(40.8)	
Income from continuing operations attributable to HealthSouth [2]	191.0	$ 2.08	219.9	$ 2.28	77.1	$ 0.58	889.8	$ 8.20
Gain on UBS Settlement	-		(121.3)		-		-	
Gov't, class action, and related settlements	(2.8)		(67.2)		36.7		1.1	
Pro fees - acct, tax, and legal	51.6		44.4		8.8		17.2	
Loss on interest rate swaps	30.4		55.7		19.6		13.3	
Provision for income tax benefit	(325.6)		(69.1)		(2.9)		(740.8)	
Interest expense and amortization of debt discounts and fees	229.2		159.3		125.7		125.6	
Depreciation and amortization	71.3		78.9		67.6		73.1	
Impairment charges, including investments	15.1		2.4		1.4		-	
Net noncash loss on disposal of assets	7.3		2.0		3.4		1.4	
Loss on early extinguishment of debt	28.2		5.9		12.5		12.3	
Stock-based compensation expense	10.6		11.7		13.4		16.4	
Other	0.4		-		0.4		0.2	
Adjusted EBITDA [1][3]	$ 306.7		$ 322.6		$ 363.7		$ 409.6	
Weighted average common shares outstanding:								
Basic		78.7		83.0		88.8		92.8
Diluted		92.0		96.4		103.3		108.5

(1) (2) (3) – Notes on page 38.

HEALTHSOUTH

Reconciliation Notes for Slides 35-37

1. Adjusted EBITDA is a non-GAAP financial measure. The Company's leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP financial measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future HealthSouth may incur expenses similar to the adjustments set forth.
2. Per share amounts for each period presented are based on diluted weighted average shares outstanding unless the amounts are antidilutive, in which case the per share amount is calculated using the basic share count after subtracting the quarterly dividend on the convertible perpetual preferred stock. The difference in shares between the basic and diluted shares outstanding is primarily related to our convertible perpetual preferred stock.
3. Adjusted EBITDA is a component of our guidance.

Adjusted EBITDA Reconciled to Net Cash Provided by Operating Activities

	Q1		Full Year				
(Millions)	2012	2011	2011	2010	2009	2008	2007
Net cash provided by operating activities	$ 81.0	$ 89.5	$342.7	$ 331.0	$406.1	$227.2	$230.6
Provision for doubtful accounts	(6.3)	(4.8)	(21.0)	(16.4)	(30.7)	(23.0)	(28.5)
Professional fees—accounting, tax, and legal	3.6	3.8	21.0	17.2	8.8	44.4	51.6
Interest expense and amortization of debt discounts and fees	23.3	35.1	119.4	125.6	125.7	159.3	229.2
UBS Settlement proceeds, gross	-	-	-	-	(100.0)	-	-
Equity in net income of nonconsolidated affiliates	3.3	2.5	12.0	10.1	4.6	10.6	10.3
Net income attributable to noncontrolling interests in continuing operations	(12.6)	(11.8)	(47.0)	(40.9)	(33.3)	(29.8)	(31.1)
Amortization of debt discounts and fees	(0.9)	(1.2)	(4.2)	(6.3)	(6.6)	(6.5)	(7.8)
Distributions from nonconsolidated affiliates	(3.3)	(2.7)	(13.0)	(8.1)	(8.6)	(10.9)	(5.3)
Current portion of income tax expense (benefit)	2.1	(2.1)	0.6	2.9	(7.0)	(72.8)	(330.4)
Change in assets and liabilities	36.9	10.9	49.9	2.8	(2.1)	50.6	5.5
Net premium paid on bond issuance/redemption	-	(4.1)	22.8	-	-	-	-
Change in government, class action and related settlements liability	-	4.3	(8.5)	2.9	11.2	7.4	171.4
Cash (provided by) used in operating activities of discontinued operations	(0.4)	(2.1)	(9.1)	(13.2)	(5.7)	(32.5)	(3.3)
Other	0.3	0.2	0.6	2.0	1.3	(1.4)	14.5
Adjusted EBITDA	$ 127.0	$117.5	$466.2	$ 409.6	$363.7	$322.6	$306.7